Mark Breidenbach
Stock Analyst at Oppenheimer
(1.66)
# 2,996
Out of 4,829 analysts
59
Total ratings
31.15%
Success rate
-1.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $10.18 | +194.70% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $1.17 | +1,011.11% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $1.70 | +900.00% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $6.52 | +1,357.06% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $1.19 | +2,000.84% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.75 | +1,231.56% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $7.88 | +2,947.62% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $3.09 | +5,077.99% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.32 | +430.30% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $0.82 | +3,811.50% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $1.93 | +677.20% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.13 | +10,566.67% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.13 | +862,731.86% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2,700 | $3.29 | +81,966.87% | 3 | Dec 13, 2019 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $10.18
Upside: +194.70%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $1.17
Upside: +1,011.11%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $1.70
Upside: +900.00%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $6.52
Upside: +1,357.06%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $1.19
Upside: +2,000.84%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.75
Upside: +1,231.56%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $7.88
Upside: +2,947.62%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $3.09
Upside: +5,077.99%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.32
Upside: +430.30%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $0.82
Upside: +3,811.50%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $1.93
Upside: +677.20%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.13
Upside: +10,566.67%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.13
Upside: +862,731.86%
Dec 13, 2019
Upgrades: Outperform
Price Target: $2,700
Current: $3.29
Upside: +81,966.87%